MX366115B - Metodos para inhibir cataratas y presbicia. - Google Patents

Metodos para inhibir cataratas y presbicia.

Info

Publication number
MX366115B
MX366115B MX2015013034A MX2015013034A MX366115B MX 366115 B MX366115 B MX 366115B MX 2015013034 A MX2015013034 A MX 2015013034A MX 2015013034 A MX2015013034 A MX 2015013034A MX 366115 B MX366115 B MX 366115B
Authority
MX
Mexico
Prior art keywords
presbyopia
methods
cataracts
inhibiting
inhibiting cataracts
Prior art date
Application number
MX2015013034A
Other languages
English (en)
Other versions
MX2015013034A (es
Inventor
Muthukumar Murugappan
Mohr Benjamin
Original Assignee
Univ Massachusetts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Massachusetts filed Critical Univ Massachusetts
Publication of MX2015013034A publication Critical patent/MX2015013034A/es
Publication of MX366115B publication Critical patent/MX366115B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0092—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin using ultrasonic, sonic or infrasonic vibrations, e.g. phonophoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hematology (AREA)
  • Medical Informatics (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En el presente documento se describen métodos para inhibir o revertir el avance de la formación de cataratas o de la presbicia en un ojo administrando un agente de enmascaramiento de carga de y-cristalinas. Tanto la presbicia como las cataratas se producen por la agregación de las proteínas del cristalino solubles llamadas cristalinas.
MX2015013034A 2013-03-14 2014-03-14 Metodos para inhibir cataratas y presbicia. MX366115B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361782860P 2013-03-14 2013-03-14
PCT/US2014/027852 WO2014152818A1 (en) 2013-03-14 2014-03-14 Methods of inhibiting cataracts and presbyopia

Publications (2)

Publication Number Publication Date
MX2015013034A MX2015013034A (es) 2016-07-05
MX366115B true MX366115B (es) 2019-06-27

Family

ID=50686164

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013034A MX366115B (es) 2013-03-14 2014-03-14 Metodos para inhibir cataratas y presbicia.

Country Status (20)

Country Link
US (3) US9789091B2 (es)
EP (1) EP2968239B1 (es)
JP (1) JP6397477B2 (es)
KR (1) KR102198622B1 (es)
CN (1) CN105209033B (es)
AU (1) AU2014236582B2 (es)
BR (1) BR112015023348B1 (es)
CA (1) CA2904657C (es)
CL (1) CL2015002689A1 (es)
CR (1) CR20150537A (es)
EA (1) EA029070B1 (es)
ES (1) ES2727293T3 (es)
HK (1) HK1218390A1 (es)
IL (1) IL241306B (es)
MX (1) MX366115B (es)
PE (1) PE20151747A1 (es)
SA (1) SA515361106B1 (es)
SG (1) SG11201507209SA (es)
WO (1) WO2014152818A1 (es)
ZA (1) ZA201506987B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968239B1 (en) 2013-03-14 2019-04-24 The University of Massachusetts Methods of inhibiting cataracts and presbyopia
CA2998134A1 (en) * 2015-09-08 2017-03-16 Viewpoint Therapeutics, Inc. Compounds and formulations for treating ophthalmic diseases
CN108348494A (zh) * 2015-11-13 2018-07-31 马萨诸塞大学 用于抑制白内障和老花眼的含peg的双官能分子
MX2021014682A (es) * 2019-05-31 2022-04-06 Plex Pharmaceuticals Inc Agentes farmacológicos para tratar enfermedades de agregación de proteínas de los ojos.
US11607064B2 (en) * 2019-08-06 2023-03-21 Dart Industries Inc. Reusable drinking straw
KR102587830B1 (ko) * 2021-07-22 2023-10-10 사회복지법인 삼성생명공익재단 딥러닝을 이용한 백내장 진단방법 및 시스템
US20230310380A1 (en) * 2022-04-05 2023-10-05 Alan Neil Glazier Methods, devices, and systems for treating lens protein aggregation diseases

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351826A (en) 1980-02-29 1982-09-28 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation using acrylamides
US4526789A (en) * 1980-02-29 1985-07-02 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation
US4665089A (en) 1985-03-21 1987-05-12 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation using protein modification reagents
US4620979A (en) 1985-08-02 1986-11-04 Schachar Ronald A Ophthalmological irrigating solution containing ascorbate
US4771036A (en) 1986-02-10 1988-09-13 Trustees Of Columbia University In The City Of New York Method and ophthalmic composition for the prevention and reversal of cataracts
CA1269327A (en) 1986-04-24 1990-05-22 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation using protein modification reagents
US5055291A (en) 1986-11-04 1991-10-08 Baylor College Of Medicine Compositions for preventing secondary cataracts
US4808182A (en) 1986-11-26 1989-02-28 Nestle, S.A. Deswelled, hydrogel intraocular lenses
US5091421A (en) 1987-06-04 1992-02-25 Massachusetts Institute Of Technology Chemical prevention or reversal of cataract by phase separation inhibitors
US5338545A (en) 1987-06-04 1994-08-16 Oculon Corporation Chemical prevention or reversal of cataract by phase separation inhibitors
US5614587A (en) * 1988-11-21 1997-03-25 Collagen Corporation Collagen-based bioadhesive compositions
DE3906311A1 (de) 1989-02-28 1990-08-30 Adatomed Pharma & Med Behandlungsystem zur verhinderung von nachstarbildung nach einer kataraktoperation
WO1992000748A1 (en) 1990-07-06 1992-01-23 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
ATE138914T1 (de) 1990-12-10 1996-06-15 Bio Physio Pharmaceutical Rese Indeno-d-pyrimidonverbindungen zur verwendung in der medizin
AU2147192A (en) 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
BR9306387A (pt) * 1992-05-20 1998-09-15 Senju Pharma Co Agente para tratar catarata e método para a sua preparação
US5375611A (en) 1993-01-26 1994-12-27 Pharmacia Ab Method for preventing secondary cataract
CN1045383C (zh) 1993-04-07 1999-10-06 王慧康 用于治疗老年性白内障的药物组合物
US5663304A (en) 1993-08-20 1997-09-02 Genentech, Inc. Refolding of misfolded insulin-like growth factor-I
DE69434617D1 (de) 1993-11-19 2006-04-06 Univ Sydney Verfahren zur prophylaxe oder kontrolle des katarakts
US5516534A (en) 1993-11-26 1996-05-14 Rensselaer Polytechnic Institute Composition and method for reducing structural defects
US5591773A (en) 1994-03-14 1997-01-07 The Trustees Of Columbia University In The City Of New York Inhibition of cataract formation, diseases resulting from oxidative stress, and HIV replication by caffeic acid esters
DE69530553T2 (de) 1994-05-13 2004-03-25 KURARAY CO., LTD, Kurashiki Medizinisches polymergel
EP0733918B1 (en) 1995-03-24 2003-07-30 Ocular Research of Boston, Inc. Hydrogel lens pre-coated with lipid layer
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
JP3599848B2 (ja) 1995-09-11 2004-12-08 株式会社メニコン 含水性軟質眼用レンズ用材料、それからなる含水性軟質眼用レンズ用成形体、ならびにそれからなる含水性軟質眼用レンズおよびその製法
EP0781777A1 (en) 1995-12-28 1997-07-02 Menicon Co., Ltd. Silicon-containing compound and ocular lens material
US5807944A (en) * 1996-06-27 1998-09-15 Ciba Vision Corporation Amphiphilic, segmented copolymer of controlled morphology and ophthalmic devices including contact lenses made therefrom
DE69714663T2 (de) 1996-06-28 2003-04-10 Ube Industries, Ltd. Verfahren zur Herstellung von Polybutadien
US5817630A (en) 1997-03-18 1998-10-06 Austin Nutriceutical Corporation Glutathione antioxidant eye drops
JPH10339857A (ja) 1997-06-05 1998-12-22 Menicon Co Ltd 薬剤徐放性コンタクトレンズの製法およびそれによってえられた薬剤徐放性コンタクトレンズ
US6015787A (en) 1997-11-04 2000-01-18 New England Medical Center Hospitals, Inc. Cell-permeable protein inhibitors of calpain
US6291466B1 (en) 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
EP1149909A1 (en) 2000-04-28 2001-10-31 Boehringer Mannheim Gmbh Methods for regulating protein conformation using molecular chaperones
US6103756A (en) 1999-08-11 2000-08-15 Vitacost Inc. Ocular orally ingested composition for prevention and treatment of individuals
CA2389917A1 (en) 1999-11-04 2001-05-10 Kazunori Kataoka A polymer micelle as monolayer or layer-laminated surface
US6835394B1 (en) 1999-12-14 2004-12-28 The Trustees Of The University Of Pennsylvania Polymersomes and related encapsulating membranes
US7977385B2 (en) 2000-03-02 2011-07-12 Numoda Biotechnologies, Inc. Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
US20020042043A1 (en) 2000-05-31 2002-04-11 Adonis Stassinopoulos Preparation of a pathogen inactivated solution of red blood cells having reduced immunogenicity
SK287787B6 (sk) 2000-12-15 2011-09-05 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Použitie L-karnitínu ako stabilizačného činidla proteínov
US6958224B2 (en) 2001-03-28 2005-10-25 Council Of Scientific And Industrial Research Chimeric protein α BNAC crystallin with extraordinarily high chaperone-like activity and a method related to the use thereof
US20030020870A1 (en) 2001-06-27 2003-01-30 Zms, Llc Biomedical molding materials from semi-solid precursors
WO2003028765A1 (fr) 2001-09-28 2003-04-10 Santen Pharmaceutical Co., Ltd. Injections pour tissu oculaire contenant un medicament lie a du polyethylene glycol
AU2003226059A1 (en) * 2002-04-10 2003-10-27 The Regents Of The University Of California Biodegradable peg-based polymer formulations in ocular applications
US6924154B2 (en) 2002-08-20 2005-08-02 Quest Diagnostics Investments Incorporated Hydrophilic chemilumescent acridinium labeling reagents
JP2004161731A (ja) 2002-09-25 2004-06-10 Nof Corp 生体関連物質用固定化剤
MXPA05009429A (es) 2003-03-05 2005-12-12 Halozyme Inc Glicoproteina hialuronidasa soluble (shasegp), proceso para preparar la misma, usos y composiciones farmaceuticas que la comprenden.
CN1621091A (zh) 2003-11-28 2005-06-01 付经国 聚乙二醇化轮状病毒体肠靶向制剂及其合成方法
EP1711510A4 (en) 2004-02-05 2008-11-26 Intradigm Corp THERAPY WITH RNAI AGENTS APPLIED IN THE TREATMENT OF OCULAR DISEASES RESULTING FROM NEOVASCULARIZATION
WO2005112977A2 (en) 2004-04-23 2005-12-01 Pharmain, Ltd. Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US7887847B2 (en) 2004-05-08 2011-02-15 Paul Jr Edward L Nutritional supplement for treatment of ocular diseases
WO2005117987A1 (en) 2004-06-01 2005-12-15 Glazier Alan N Antibody conjugates targeting to ocular proteins
US6945971B1 (en) 2004-07-19 2005-09-20 Gwon Arlene E Controlled ocular lens regeneration
CA2583231A1 (en) * 2004-11-04 2006-05-18 University Of Washington Compositions and methods for treatment of protein misfolding and protein aggregation diseases
US7741311B2 (en) 2005-01-03 2010-06-22 Shaker Mousa Composition and method for treating occlusive vascular diseases, nerve regeneration, and wound healing
CN1660920A (zh) 2005-02-01 2005-08-31 华东理工大学 末端连接ω－氨基酸的聚乙二醇酸或活性酯及制法和应用
DE102005041570A1 (de) 2005-09-01 2007-03-22 Celares Gmbh Hoch verzweigte Reagenzien zur Modifaktion von Biopharmazeutika, deren Herstellung und Anwendung
US7832875B2 (en) 2005-09-29 2010-11-16 Virtek Vision International Inc. Modulated diode pumped microchip laser projector
US20080094573A1 (en) 2006-04-04 2008-04-24 Vermette Patrick Surface-modified materials, such as contact lenses, methods and kits for their preparation, and uses thereof
US20070275098A1 (en) 2006-05-19 2007-11-29 T.R.P. Company, Inc, A Nevada Corporation Formulation and methodology for the treatment for eye impairment symptoms
WO2008145721A2 (en) * 2007-06-01 2008-12-04 Novo Nordisk A/S N-terminal modification of polypeptides for protection against degradation by aminopeptidases
WO2009029991A1 (en) 2007-09-07 2009-03-12 Meat & Livestock Australia Limited Agents with angiogenic and wound healing activity
JPWO2009051223A1 (ja) 2007-10-19 2011-03-03 株式会社アールテック・ウエノ 白内障処置のための医薬組成物
KR20100000203A (ko) 2008-06-24 2010-01-06 인하대학교 산학협력단 금나노입자를 이용한 표적지향형 항암약물전달체
AU2009265021A1 (en) 2008-06-30 2010-01-07 Johnson & Johnson Vision Care, Inc. Methods and ophtalmic devices used in the treatment of ocular allergies
ES2572891T3 (es) * 2008-07-14 2016-06-02 Biocon Limited Un método de síntesis de una mezcla sustancialmente monodispersadada de oligómeros
WO2010065024A1 (en) 2008-12-05 2010-06-10 Kador Peter F Topical treatment of cataracts in dogs
EP3246048B1 (en) * 2009-02-18 2024-04-03 Calm Water Therapeutics LLC Bi-functional co-polymer use for ophthalmic applications
WO2010130638A1 (en) 2009-05-14 2010-11-18 Evotec Ag Sulfonamide compounds, pharmaceutical compositions and uses thereof
US8758802B2 (en) 2009-12-14 2014-06-24 University Of Massachusetts Methods of inhibiting cataracts and presbyopia
WO2011133566A2 (en) 2010-04-19 2011-10-27 University Of Louisville Research Foundation, Inc. Repairing bruch's membrane with hydrogels
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
CN102172410B (zh) 2011-01-14 2013-08-07 华南理工大学 用于癌症诊断与治疗的靶向纳米粒传输系统的构建方法
CN102634492B (zh) 2011-02-14 2015-06-10 重庆富进生物医药有限公司 聚乙二醇化犬源尿酸氧化酶类似物及其制备方法和应用
WO2012135682A2 (en) * 2011-03-31 2012-10-04 Dh Technologies Development Pte. Ltd. Composition, method, and kit for calibrating a mass spectrometer
WO2012142659A1 (en) 2011-04-19 2012-10-26 Baker Idi Heart And Diabetes Institute Holdings Limited Site-selective modification of proteins
JP6415979B2 (ja) 2011-06-03 2018-10-31 スリーエム イノベイティブ プロパティズ カンパニー ヒドラジノ１ｈ−イミダゾキノリン−４−アミン及びこれから調製された複合体
CN202172410U (zh) 2011-08-23 2012-03-21 东莞市铭普实业有限公司 一种基于物联网的带按键的射频智能光模块
AU2012302637B2 (en) 2011-09-04 2016-09-15 Glytech, Inc. Glycosylated polypeptide and drug composition containing said polypeptide
JP2014528465A (ja) 2011-10-12 2014-10-27 アセンディス ファーマ オフサルモロジー ディヴィジョン エー／エス 眼の状態の予防及び治療
CN102579353B (zh) 2012-03-30 2013-12-04 吉林大学 叶酸靶向的抗癌药物peg修饰的脂质体及制备方法
CA2884910C (en) 2012-10-11 2021-07-13 Ascendis Pharma Ophthalmology Division A/S Vegf neutralizing prodrugs for the treatment of ocular conditions
EP2915001A4 (en) 2012-11-01 2016-05-04 Univ Johns Hopkins CONTACT LENS SURFACE MODIFICATION BY HYALURONIC ACID (HA) BINDING PEPTIDE FOR ACCUMULATION AND HA RETENTION
EP2968239B1 (en) 2013-03-14 2019-04-24 The University of Massachusetts Methods of inhibiting cataracts and presbyopia
WO2014171842A1 (en) 2013-04-19 2014-10-23 Living Cell Technologies New Zealand Limited Biocompatible encapsulation system
WO2015085173A1 (en) 2013-12-05 2015-06-11 Wu Nian Polymer-carbohydrate conjugates for drug delivery technology
CN108348494A (zh) 2015-11-13 2018-07-31 马萨诸塞大学 用于抑制白内障和老花眼的含peg的双官能分子

Also Published As

Publication number Publication date
JP2016517428A (ja) 2016-06-16
AU2014236582A1 (en) 2015-11-05
IL241306A0 (en) 2015-11-30
ZA201506987B (en) 2016-12-21
EP2968239A1 (en) 2016-01-20
HK1218390A1 (zh) 2017-02-17
EP2968239B1 (en) 2019-04-24
CN105209033B (zh) 2018-09-18
CL2015002689A1 (es) 2016-02-05
MX2015013034A (es) 2016-07-05
US10413529B2 (en) 2019-09-17
SG11201507209SA (en) 2015-10-29
BR112015023348A2 (pt) 2017-07-18
PE20151747A1 (es) 2015-12-18
WO2014152818A1 (en) 2014-09-25
CN105209033A (zh) 2015-12-30
KR102198622B1 (ko) 2021-01-05
NZ713007A (en) 2020-11-27
US20160074370A1 (en) 2016-03-17
US20160000707A1 (en) 2016-01-07
JP6397477B2 (ja) 2018-09-26
ES2727293T3 (es) 2019-10-15
US9675589B2 (en) 2017-06-13
SA515361106B1 (ar) 2018-09-25
KR20150130361A (ko) 2015-11-23
US9789091B2 (en) 2017-10-17
CR20150537A (es) 2015-11-27
EA201591677A1 (ru) 2016-01-29
IL241306B (en) 2019-11-28
US20170231905A1 (en) 2017-08-17
EA029070B1 (ru) 2018-02-28
CA2904657C (en) 2021-02-16
CA2904657A1 (en) 2014-09-25
AU2014236582B2 (en) 2018-03-29
BR112015023348B1 (pt) 2023-04-25

Similar Documents

Publication Publication Date Title
MX2015013034A (es) Metodos para inhibir cataratas y presbicia.
IL276016B (en) Ocular formulations for administration of drug to the back of the eye
EP3413851A4 (en) EYE INJECTION KIT, PACKAGING AND METHODS OF USE
EP3229735A4 (en) Intraocular lens injector
MX363913B (es) Inhibidores de bromodominio tetraciclicos.
EP3319553A4 (en) Intraocular lenses (iols) and related assemblies and intraocular attachment methods
MX2015012158A (es) Inhibidores de bomodominio tetraciclicos fusionados.
MX2023003124A (es) Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas.
TWD159203S (zh) 眼內鏡片植入具之部分
PL3100101T3 (pl) Wieloogniskowa soczewka okulistyczna do noszenia w lub na oku
ES2981342T3 (es) Modelo ocular
IL282504A (en) Ocular formulations for drug administration and protection of the front part of the eye
NZ728131A (en) Aqueous ophthalmic composition
PL3720428T3 (pl) Kompozycja oftalmiczna do podawania miejscowego zawierająca kwas dobezylowy do leczenia chorób tylnego odcinka oka
MX2018003799A (es) Nueva composicion oftalmica que contiene rebamipida y metodo para prepararla.
TR201902864T4 (tr) Beta-klorosiklopentanların hidrofilik ester ön ilaçlarının kullanımı ile azaltılmış merkezi korneal kalınlaşma.
TWD159204S (zh) 眼內鏡片保持具之部分
RU2012151092A (ru) Способ проведения иридэктомии
ES1244404Y (es) Protesis ocular antialergica
EP3170500A4 (en) Prophylactic or therapeutic agent for diseases of posterior segment of eye
UA90070U (ru) Способ профилактики возникновения макулярного отека после проведения факоэмульсификации катаракты
ECSDI15000900S (es) Diseño de moqueta [ii]
UA63205U (ru) Способ трансцилиарной закрытой иридопластики у больных с посттравматической патологией хрусталика, радужки и стекловидного тела
TWD159197S (zh) 眼內鏡片植入具
TWD159202S (zh) 眼內鏡片植入具之部分

Legal Events

Date Code Title Description
FG Grant or registration